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Abstract
Prion diseases are characterized by the conformational 
transition of the cellular prion protein (PrPC) into an aberrant 
protein conformer, designated scrapie-prion protein 
(PrPSc). A causal link between protein misfolding and 
neurodegeneration has been established for a variety of 
neurodegenerative disease, such as Alzheimer's disease, 
Parkinson's disease and polyglutamine diseases, but there 
is an ongoing debate about the nature of the neurotoxic 
species and how non-native conformers can damage 
neuronal populations. PrP is normally imported into the 
endoplasmic reticulum (ER) and targeted to the outer leaflet 
of the plasma membrane via a glycosylphosphatidylinositol 
(GPI) anchor. However, several conditions, such as ER 
stress or some pathogenic mutations in the PrP gene, can 
induce the mislocalization of PrP in the cytosol, where it has 
a neurotoxic potential as demonstrated in cell culture and 
transgenic mouse models. In this review we focus on intrinsic 
factors and cellular pathways implicated in the import of PrP 
into the ER and its mistargeting to the cytosol. The findings 
summarized here not only reveal a complex regulation of 
the biogenesis of PrP, but also provide interesting new 
insight into toxic activities of pathogenic protein conformers 
and quality control pathways of ER-targeted proteins.
Introduction
Prion diseases are a group of transmissible 
neurodegenerative disorders including Creutzfeldt-Jakob 
disease (CJD) and Gerstmann-Sträussler-Scheinker 
syndrome (GSS) in humans, scrapie in sheep and goat, 
bovine spongiform encephalopathy (BSE) in cattle and 
chronic wasting disease (CWD) in free-ranging deer. A 
hallmark of prion diseases is the conversion of the cellular 
prion protein PrPC into its misfolded isoform, termed PrPSc. 
Similarly to other neurodegenerative diseases, there is an 
ongoing debate whether folding intermediates, oligomers, 
amorphous or fibrillar aggregates are the neurotoxic 
species (rev. in (Caughey and Lansbury, 2003; Haass and 
Selkoe, 2007; Winklhofer et al., 2008). A unique feature of 
prion diseases is their transmissibility, which is also linked to 
PrPSc constituting the main component of infectious prions 
(reviewed in Aguzzi and Polymenidou, 2004; Chesebro, 
2003; Collinge, 2001; Prusiner et al., 1998; Weissmann et al., 
1996). In the majority of prion diseases there is a correlation 
between the accumulation of misfolded PrP, formation of 
infectious prions and neurodegeneration, however, there 
are some interesting exceptions. Transgenic mouse models 
revealed that several PrP mutants can induce neuronal 
cell death in the absence of infectious prion propagation 
(Baumann et al., 2007; Chiesa et al., 1998; Flechsig et al., 
2003; Hegde et al., 1998; Li et al., 2007; Ma et al., 2002; 
Muramoto et al., 1997; Shmerling et al., 1998). Vice versa 
it has been shown that propagation of infectious prions can 
occur in the absence of clinical signs (Brandner et al., 1996; 
Chesebro et al., 2005; Mallucci et al., 2003). Consequently, 
it appears plausible that the infectious particle and the 
neurotoxic agent might be two distinct species/conformers.
 In this review we focus on a specific class of pathogenic 
PrP conformers that are characterized by a toxic potential 
in the cytosolic compartment. We summarize our current 
knowledge about PrP domains and cellular pathways 
regulating the translocation of PrP into the ER and 
pathophysiological consequences of PrP accumulation in 
the cytosol.
PrP-mediated neurodegeneration: a cytosolic 
connection
Several studies indicated that PrP can acquire a neurotoxic 
potential when its import into the ER is partially or completely 
compromised. Employing in vitro models Lingappa and 
coworkers demonstrated that during import into the ER, 
PrP can attain two different transmembrane topologies 
with either the N- or C-terminal domain facing the cytosol 
(Yost et al., 1990) (see below). A transgenic mouse model 
revealed that preventing the import of PrP into the ER leads 
to the formation of a neurotoxic PrP species in the cytosol. 
Mice expressing a PrP mutant lacking the N-terminal ER 
targeting signal (cytoPrP) acquired severe ataxia due to 
rapid cerebellar granule neuron degeneration (Ma et al., 
2002). A recent study supported this activity of cytoPrP 
and demonstrated that neurotoxicity of cytoPrP is also 
seen in different neuronal populations (Wang et al., 2009). 
Cytotoxic effects of cytoPrP were also observed in several 
mammalian cell culture models (Ma et al., 2002; Rambold 
et al., 2006; Rane et al., 2004). Further support for a toxic 
potential of cytosolically localized PrP was obtained in a 
yeast model. During post-translational targeting of PrP to 
the ER, PrP was missorted to the cytosol and interfered with 
yeast growth (Heller et al., 2003).
 So far, mutations within the N-terminal signal sequence 
of PrP, which could affect the efficiency of ER import, have 
not been identified in patients suffering from prion diseases. 
However, the pathogenic PrP-W145Stop mutant, linked to 
Gerstmann-Sträussler-Scheinker syndrome in humans, 
has been reported to localize to the cytosolic and nuclear 
compartment (Zanusso et al., 1999). A different study 
including another pathogenic mutant, PrP-Q160Stop, 
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corroborated these findings and provided the first evidence 
that information in the C-terminal domain of PrP is necessary 
and sufficient for ER import (Heske et al., 2004) (see 
below).
Quality control of secretory proteins
As outlined above, alterations in protein folding, processing 
and/or degradation are common features of prion diseases 
as well as other neurodegenerative disorders, implying a role 
of quality control systems, such as molecular chaperones 
and the ubiquitin-proteasome pathway in the removal 
of neurotoxic protein conformers (rev. in (Ciechanover 
and Brundin, 2003; Morimoto, 2008). In the cytosol the 
ubiquitin-proteasome system (UPS) is the main pathway for 
regulated protein turnover (rev. in (Ciechanover et al., 2000; 
Hershko and Ciechanover, 1998; Pickart, 2001). Moreover, 
the proteasome mediates post-translational degradation of 
non-native proteins generated in the ER as part of a quality 
control system, designated ER-associated degradation 
(ERAD). This pathway involves recognition of non-native 
polypeptides by ER-resident chaperones and retrograde 
transport to the cytosol where proteasomal degradation 
occurs (rev. in (Ellgaard and Helenius, 2003; Meusser et 
al., 2005; Nakatsukasa and Brodsky, 2008). In case ERAD 
substrates accumulate in the ER lumen, intracellular signaling 
pathways are induced, collectively called the unfolded 
protein response (UPR) (rev. in (Malhotra and Kaufman, 
2007; Ron and Walter, 2007). Only little is known about 
quality control pathways of GPI-anchored proteins, such as 
PrP. Interestingly, a pre-emptive, co-translocational quality 
control pathway was described recently, which operates 
before translocation into the ER is completed (Kang et al., 
2006; Oyadomari et al., 2006). Regulated translocation 
could act as an early quality control step to prevent an 
overload of the ER with non-native proteins, specifically 
during an imbalance in cellular homeostasis. Indeed, it has 
been shown that PrP can be co-translocationally re-directed 
to proteasomal degradation during conditions of acute ER 
stress (Kang et al., 2006; Orsi et al., 2006). 
Import of PrP into the endoplasmic reticulum: the role 
of PrP domains
The N-terminal ER signal sequence
The primary signal to target PrP to the ER is a N-terminal 
signal sequence (aa 1-22), which is recognized and bound 
by the signal recognition particle (SRP). SRP interaction 
with both the emerging polypeptide chain and the ribosome 
results in pausing of elongation and targeting of the 
ribosome-nascent chain complex to the Sec61 translocon. 
After binding of SRP to its receptor at the ER membrane, 
protein synthesis proceeds and transfer of the polypeptide 
chain into the ER lumen occurs in a co-translational manner 
(Gilmore et al., 1982a; Gilmore et al., 1982b; Meyer and 
Dobberstein, 1980; Walter and Blobel, 1980; Walter and 
Blobel, 1982; Walter et al., 1984).
  ER import can be mediated by a remarkably diverse 
set of signal sequences, and it has been demonstrated 
for various secretory pathway proteins that translocation 
efficiency is regulated in a signal peptide sequence-specific 
manner (rev. in (Hegde and Bernstein, 2006; Martoglio 
and Dobberstein, 1998; von Heijne, 1985). Indeed, the 
sequence of the ER signal peptide has a significant impact 
on the import efficiency and the formation of topological 
isoforms of PrP. The first hint that PrP can be synthesized 
in topologies others than the GPI-anchored form emerged 
from in vitro studies (Yost et al., 1990). Two different 
topologies, termed NtmPrP (N-terminus facing the ER lumen) 
or CtmPrP (C-terminus facing the ER lumen) were described 
with the internal hydrophobic (HD) domain (amino acids 
112 - 135) serving as a putative transmembrane domain. 
Mutations within the internal HD or the N-terminal signal 
peptide were found to alter the relative amount of CtmPrP 
and NtmPrP (Hegde et al., 1998; Kim et al., 2001; Stewart et 
al., 2001). Interestingly, increased synthesis of CtmPrP has 
been shown to coincide with progressive neurodegeneration 
both in Gerstmann-Sträussler-Scheinker syndrome (GSS) 
patients with an A117V mutation and in transgenic mice 
carrying a triple mutation within the hydrophobic domain 
(AAA113,115,118VVV, in short AV3) (Hegde et al., 1998; 
Stewart et al., 2005). For a more detailed description of 
CtmPrP and other neurotoxic PrP mutants, please see the 
review by Harris and colleagues in the same issue.
 The role of the ER signal sequence and the HD in 
the ER import efficiency of PrP was further emphasized 
when we expressed mammalian PrP in Saccharomyces 
cerevisiae. Due to the relatively low hydrophobicity index 
(Kyte-Doolittle) of the signal peptide, PrP was targeted to 
the ER via a post-translational pathway in yeast cells . As a 
consequence, ER import was impaired and the accumulation 
of PrP in the cytosol interfered with cell viability. By using 
a more hydrophobic signal peptide or by deleting the HD, 
import of PrP into the ER as well as and yeast growth could 
be restored (Heller et al., 2003).
The internal hydrophobic domain (HD)
The internal HD (aa 112-135) of PrP was first described as a 
putative transmembrane domain (Lopez et al., 1990). Later 
it was shown that mutations within the HD can alter the 
relative amount of CtmPrP and NtmPrP (Hegde et al., 1998; 
Kim et al., 2001; Stewart et al., 2001). Moreover, different 
models revealed that this stretch of hydrophobic amino 
acids has additional properties: 1. Short peptides comprising 
amino acid residues 106-126 form fibrils in vitro (Tagliavini 
et al., 1993) and induce cell death in cultured cells (Brown 
et al., 1996; Deli et al., 2000; Forloni et al., 1993; Haïk et 
al., 2000). 2. In polarized cells the HD confers basolateral 
sorting in a dominant manner (Uelhoff et al., 2005). 3. 
Transgenic mice expressing PrP mutants lacking the HD 
(PrP?HD) spontaneously develop a non-transmissible 
neurodegenerative disease (Baumann et al., 2007; Li et al., 
2007; Shmerling et al., 1998). 4. The HD is linked to the toxic 
activity of cytosolically localized PrP (Rambold et al., 2006) 
(see below). Moreover, we have recently shown that the HD 
promotes dimer formation of PrP, which is associated with 
its stress-protective activity (Rambold et al., 2008).
The C-terminal GPI signal peptide
Biochemical studies using purified PrPSc revealed that PrP 
is modified with a glycosylphosphatidylinositol (GPI) anchor 
(Stahl et al., 1987). GPI modification occurs in the ER via 
removal of a C-terminal signal peptide and the replacement 
with a pre-formed GPI anchor at an acceptor amino acid, 
called ? site. This reaction is catalyzed by a transamidase 
that resides within the ER membrane (Amthauer et al., 1993; 
Eisenhaber et al., 1998; Englund, 1993; Udenfriend and 
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Kodukula, 1995). Similarly to the N-terminal signal peptides, 
the C-terminal GPI anchor signal sequences do not share 
conserved consensus sequences but rather characteristic 
features. Only a few amino acids with small side chains 
are allowed at the ?, the ?+1 and the ?+2 positions, and 
a hydrophobic domain is required about 10-12 amino acids 
distal to the ? site (Ferguson and Williams, 1988; Kodukula 
et al., 1993; Moran et al., 1991; Nuoffer et al., 1993; Nuoffer 
et al., 1991).
 Deletion of the C-terminal GPI anchor signal sequence 
prevents membrane attachment of PrP?GPI (also known 
as PrP-S230X or GPI-PrP), but does not interfere with 
ER import or further trafficking of PrP?GPI through the 
secretory pathway (Blochberger et al., 1997; Rogers et al., 
1993; Winklhofer et al., 2003). PrP?GPI is secreted both 
by cultured cells (Winklhofer et al., 2003) and by neurons 
of transgenic mice (Chesebro et al., 2005). However, 
membrane anchoring of PrP, be it via the authentic GPI 
anchor or via a heterologous CD4 transmembrane domain is 
required to ensure efficient modification of PrP with N-linked 
glycans of complex structure (Winklhofer et al., 2003).
 Interestingly, the C-terminal GPI anchor signal peptide 
has been reported to mediate targeting of PrP to the ER. 
Initial results obtained in vitro indicated that the C-terminal 
signal peptide can promote post-translational translocation 
of PrP into the ER (Holscher et al., 2001). These findings 
were recently corroborated in cultured cells, moreover, it 
was shown that the GPI signal sequence can mediate co-
translational ER targeting when located at the N-terminus of 
PrP or heterologous proteins (Gu et al., 2008).
The structured C-terminal domain
Structural studies on recombinant PrP indicated a particular 
modular composition (Figure 1A): the N-terminal domain of 
Figure 1. (A) Schematic presentation of the mammalian prion protein. ER-SS: ER signal sequence, ?1-3: ?-helical regions, 
?1, 2: ?-strands, CHO: N-linked glycosylation acceptor site, GPI-SS: GPI anchor signal sequence, straight line: unstructured 
regions. Gray boxes mark domains implicated in the import of PrP into the ER. (B) The C-terminal structured domain is 
necessary and sufficient for effcient translocation into the ER. The scheme illustrates the ER import efficiency of different PrP 
mutants with deletions in the C- or N-terminal domain. While a deletion of the unstructured N-terminus and/or of the C-terminal 
GPI anchor signal sequence (PrP?GPI, PrP?N?GPI) does not impair translocation of PrP the import efficiency successively 
decreased by increasing the deletions in the C-terminal structured domain.
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PrP spanning 120 amino acids is flexibly disordered followed 
by a highly structured C-terminal domain of approximately 
110 amino acids. This autonomously folding domain contains 
three ?-helical regions and a short, two-stranded ?-sheet 
(Donne et al., 1997; Riek et al., 1996; Riek et al., 1997). The 
analysis of PrP-W145Stop, a pathogenic PrP mutant linked 
to Gerstmann-Sträussler-Scheinker syndrome in humans, 
provided the first hint that a loss of the C-terminal domain 
interferes with ER import of PrP: PrP-W145Stop was found 
in the cytosolic and nuclear compartment (Zanusso et al., 
1999). Further studies including a different pathogenic 
mutant, PrP-Q160Stop, corroborated these findings and 
revealed that information in the C-terminal domain of PrP 
is necessary and sufficient for its import into the ER (Heske 
et al., 2004). We could now show that it is the presence 
of alpha-helical domains in the C-terminus that promotes 
ER import of PrP. The study revealed that after targeting 
to the translocon the secondary structure of the nascent 
polypeptide chain can significantly modulate translocation 
efficiency. ER-targeted polypeptides dominated by 
unstructured domains failed to efficiently translocate into the 
ER lumen and were subjected to proteasomal degradation 
via a co-translocational/pre-emptive pathway (Miesbauer et 
al., 2009).
Toxic PrP conformers in the cytosol
cytoPrP
A convincing model to demonstrate the neurotoxic capacity of 
cytosolically localized PrP (cytoPrP) was initially generated 
by Lindquist and coworkers: Mice expressing a PrP mutant 
with a deleted N-terminal ER targeting signal sequence 
acquire severe ataxia due to cerebellar degeneration (Ma 
et al., 2002). Importantly, in a different transgenic mouse 
model toxicity of cytoPrP was also demonstrated in other 
neuronal populations (Wang et al., 2009). Cell culture 
studies indicated that toxicity of cytoPrP seems to be 
dependent on its association with intracellular membranes 
(Wang et al., 2006) and its binding to Bcl-2, an anti-apoptotic 
protein present at the cytosolic side of ER and mitochondrial 
membranes (Rambold et al., 2006). Brain extracts from 
clinically ill transgenic mice expressing cytoPrP do not 
contain infectious prions, a phenomenon also seen in other 
transgenic mouse models of neurotoxic PrP mutants (rev. 
in (Winklhofer et al., 2008). In this context it should also be 
noted that cytosolically localized PrP seems to be present 
in a subset of neurons even under physiological conditions 
(Mironov et al., 2003).
PrPSc
The scrapie-prion protein or PrPSc was originally identified 
as a protease-resistant protein in brain extracts that co-
purifies with the infectious scrapie agent (Bolton et al., 
1982). In contrast to PrPC, PrPSc is insoluble in non-ionic 
detergents, partially resistant to proteolytic digestion and 
characterized by a high content of ?-sheet secondary 
structure (Caughey et al., 1991; Meyer et al., 1986; Pan et al., 
1993). While PrPSc seems to be sufficient for the formation 
of infectious prions, elegant grafting experiments provided 
the first evidence that PrPSc is not toxic to neurons lacking 
PrPC (Brandner et al., 1996), a finding later supported by 
conditional cell-type specific PrP knockout mice (Mallucci 
et al., 2003) and transgenic mice expressing PrP?GPI, 
an anchorless PrP mutant (Chesebro et al., 2005). We 
have recently established a new cell culture model, which 
corroborates the observations from the mouse models 
and supports the notion that PrPSc is only toxic to cells 
expressing PrPC (Rambold et al., 2008). Based on these 
findings, two plausible scenarios for the toxic effects of 
PrPSc can be envisaged, which are not mutually exclusive: 
Either neurotoxicity of PrPSc is linked to its propagation in 
neuronal cells, which is dependent on the expression of 
PrPC, and/or PrPSc elicits a deadly signal through a PrPC-
dependent signaling pathway. Employing mouse models, 
cell culture and in vitro approaches, Tabrizi and colleagues 
provided support for the notion that during a prion infection 
misfolded PrP can translocate into the cytosol of the infected 
cells and induce toxic effects by inhibiting the proteasome 
(Kristiansen et al., 2007). 
ER-targeted PrP can be re-directed to the cytosol via a 
co-translocational pathway
The cytosolic localization of ER proteins is usually linked to a 
cellular quality control system involving retrograde transport 
and subsequent proteasomal degradation, designated ER-
associated degradation (ERAD). This pathway is designed 
to ensure cellular homeostasis and to preclude toxic 
effects of aberrant protein conformers within the ER. The 
accumulation of PrP in the cytosol after prolonged inhibition 
of proteasomal activity was initially interpreted as evidence 
for retrograde transport of PrPC from the ER lumen into 
the cytosol (Ma and Lindquist, 2001; Yedidia et al., 2001). 
This conclusion, however, was discussed controversially 
after cytosolic accumulation of PrP has been proposed to 
be an experimental artifact, due to the prolonged treatment 
of cells with proteasomal inhibitors and overexpression 
of PrP driven by a viral promotor (Drisaldi et al., 2003). 
Based on our studies in yeast and mammalian cells we 
proposed that impaired ER import rather than retrograde 
translocation from the ER is responsible for the formation 
of cytosolic PrP (Heller et al., 2003; Heske et al., 2004; 
Tatzelt and Winklhofer, 2004) (Figure 1B). This concept was 
substantiated by recent studies showing that in addition to 
ERAD a co-translocational or pre-emptive quality control 
pathway exists, which interferes with the translocation 
of secretory pathway proteins into the ER lumen (Kang 
et al., 2006; Oyadomari et al., 2006). As a consequence, 
such a co-translocation quality control pathway reduces 
the amount of non-native substrates in the ER lumen and 
thereby unburdens the luminal ER quality control machinery. 
This could be particularly beneficial under conditions of ER 
stress in order to reduce the ER protein folding load (Kang 
et al., 2006).
 Support for the idea that PrP is targeted via a co-
translocational pathway to the cytosol was the observation 
that the cytosolic PrP fraction contained an uncleaved 
signal peptide (Heske et al., 2004; Miesbauer et al., 2009; 
Rambold et al., 2006; Zanusso et al., 1999). Processing 
of the N-terminal signal peptide and the transfer of core 
glycans occur co-translocationally prior to the release of 
the polypeptide into the ER lumen (rev. in (Kornfeld and 
Kornfeld, 1985). Thus, an uncleaved signal peptide is 
indicative for an abrogated translocation event. Interestingly, 
an uncleaved signal peptide was also described for CtmPrP 
(Kim and Hegde, 2002; Stewart et al., 2001). Moreover, 
it has been shown that an uncleaved signal peptide is a 
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characteristic feature of other substrates subjected to the 
co-translocational/pre-emptive pathway (Oyadomari et al., 
2006; Rutkowski et al., 2007).
 Why is it interesting that PrP seems to be subjected to 
a co-translocational quality control pathway? Little is known 
about quality control pathways of non-native or misfolded 
GPI-anchored proteins and ERAD in mammalian cells 
has mainly been studied with transmembrane proteins. 
Indeed, experimental evidence suggests that PrP is a poor 
ERAD substrate. In particular, PrP lacking a GPI anchor 
is misfolded and incompletely glycosylated, however, it is 
efficiently transported through the secretory pathway and 
finally secreted (Blochberger et al., 1997; Chesebro et al., 
2005; Rogers et al., 1993; Walmsley et al., 2001; Winklhofer 
et al., 2003). This observation suggests that PrP?GPI is not 
sensed as misfolded by the cellular quality control systems in 
the ER lumen. Two observations support such a hypothesis. 
Firstly, the terminal glucose residues are removed from 
the core glycans of PrP?GPI and secondly, even the 
overexpression of PrP?GPI does not result in the activation 
of the unfolded protein response (UPR) (Winklhofer et al., 
2003). A recent study supports the idea that misfolded 
conformers of PrP generated in the ER lumen are neither 
recognized by ER quality control pathways nor routed to 
ERAD. Instead, mutant PrPs trafficked to the Golgi, from 
where the misfolded subpopulation was selectively trafficked 
for degradation in acidic compartments (Ashok and Hegde, 
2009).
 Which conditions might impair the import of PrP into the 
ER? Regarding the ER import mechanism, it is important to 
note that translocation of PrP into the ER seems to be more 
complex than that of other secretory proteins. In vitro studies 
using reconstituted lipid vesicles revealed that ER import 
of PrP requires the translocon-associated protein (TRAP) 
complex in addition to the essential translocon components 
Sec61 complex, the signal recognition particle receptor and 
the translocating chain associated protein (TRAM) (Fons 
et al., 2003). Consistent with the idea that an imbalance 
of cellular homeostasis brings a co-translocational quality 
control pathway on the scene (Rutkowski et al., 2007), the 
accumulation of cytosolic PrP containing an uncleaved 
signal peptide was favored under conditions of ER stress 
(Kang et al., 2006; Orsi et al., 2006).
Figure 2. Pathways implicated in the fomation of cytosolically localized PrP. After targeting of the ribosome-nascent chain 
complex to the translocon the N-terminal signal peptide initiates the translocation process. 1: Under physiological conditions 
PrP is translocated into the ER lumen. During import the N-terminal signal peptide is cleaved off and two N-linked glycans 
are attached. Shortly after release into the ER lumen the C-terminal signal sequence is removed and replaced with a pre-
formed GPI anchor. During transit through the secretory pathway the core glycans are converted into complex structures 
and PrPC is finally targeted to the outer leaflet of the plasma membrane. In scrapie-infected cells, PrPC at the cell surface or 
along the endocytic pathways interacts with and is converted into PrPSc. 2: The classical ERAD pathway would involve retro-
translocation of non-native or misfolded conformers of PrP present in the ER lumen into the cytosol. The N-linked glycans 
are removed by a cytosolic N-glycanase prior to proteasomal degradation. 3: In a co-translocational quality control pathway 
productive translocation of the growing polypetide chain into the ER is not pursued. Instead the protein is directly targeted 
to proteasomal degradation. Proteins subjected to this pathway would retain their N-terminal signal peptide. 4: In scrapie-
infected cells oligomeric species of PrPSc might translocate from the plasma membrane or endocytic compartments to the 
cytosol where they interfere with proteasomal activity.
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Pathophysiological consequences of cytosolically 
localized PrP
A transgenic mouse model and various cell culture 
approaches provided convincing evidence that cytosolic PrP 
can have a toxic potential, however, two major questions 
have remained unanswered. First, does cytosolic PrP play a 
role in the pathogenesis of prion diseases and second, how 
does PrP in the cytosol induce neuronal cell death?
 In this context it is important to remember that cytoPrP 
is biochemically quite different from infectious PrPSc. 
CytoPrP does adopt a misfolded and partially proteinase 
K (PK)-resistant conformation, however, it lacks post-
translational modifications, like the GPI anchor and N-linked 
carbohydrates. Moreover, it does not seem to be infectious. 
A similar biochemical signature was described for PrP?GPI. 
However, PrP?GPI is efficiently imported into the ER 
and has no toxic activity in cultured cells (Rambold et al., 
2006) nor does it cause neurodegeneration in transgenic 
mice (Chesebro et al., 2005). Based on these findings 
we established a cell culture model to identify cellular 
components linked to the toxic activity of cytoPrP (Rambold 
et al., 2006). Interestingly, an interaction of PrP and Bcl-2 
was described previously for recombinantly expressed 
proteins (Kurschner and Morgan, 1995, 1996). We could 
verify such an interaction in neuronal cells and showed 
that the recruitment of Bcl-2 to misfolded PrP provides a 
plausible explanation for the toxic potential of cytoPrP 
(Rambold et al., 2006). A different study revealed that 
toxicity of cytoPrP seems to be dependent on its association 
with intracellular membranes (Wang et al., 2006), the locale 
where Bcl-2 resides. Regarding the role of Bcl-2 in cytoPrP-
mediated toxicity, two scenarios are conceivable. Bcl-2 may 
be inactivated by its sequestration into cytoPrP aggregates. 
In support of this possibility, recent results from our group 
indicated that cytoPrP can displace Bax from a Bcl-2/Bax 
complex (Rambold et al, unpublished results). Alternatively, 
binding of Bcl-2 to cytoPrP may induce a conformational 
change of Bcl-2, converting it into a pro-apoptotic protein. 
Evidence for opposing phenotypes of Bcl-2 was provided 
by Lin et al., who showed that the interaction with Nurr77 
converts Bcl-2 from a protector to a killer protein (Lin et al., 
2004).
 Two additional findings need to be considered in the 
context of cytoPrP-induced toxicity. First, binding of Bcl-2 
to PrP, as well as the toxic potential of cytoPrP could be 
mitigated by the increased expression of Hsp70 and its co-
chaperone Hsp40, indicating a protective role of chaperones 
in PrP-induced toxicity (Rambold et al., 2006). Second, 
several cell culture models indicated that toxicity of cytoPrP 
is markedly enhanced under conditions of proteasomal 
impairment, suggesting that under physiological conditions 
the accumulation of cytoPrP is efficiently controlled (Ma et 
al., 2002; Rambold et al., 2006; Rane et al., 2004; Wang et 
al., 2005; Yedidia et al., 2001). This multifaceted influence 
on the formation and clearance of cytoPrP, which seems to 
be highly dependent on the cellular homeostasis, provides a 
plausible explanation for the discrepant findings in different 
reports on the toxic potential of cytosolic PrP (Fioriti et al., 
2005; Roucou et al., 2003). In a different study it was shown 
that both CtmPrP  and cytoPrP can interact with and disrupt 
the function of Mahogunin, a cytosolic ubiquitin ligase 
whose loss causes spongiform neurodegeneration in mice 
(Chakrabarti and Hegde, 2009). 
 Interestingly, it was proposed that PrPSc might also 
exert its toxic potential in the cytosol.Tabrizi and colleagues 
showed that ?-sheet-rich conformers of recombinant PrP 
and semi-purified PrPSc from prion-infected mouse brains 
inhibited the 26S proteasome in vitro. Moreover, proteasomal 
activity was decreased in prion-infected cells and in scrapie-
diseased mouse brain (Kristiansen et al., 2007). This 
study not only might help to unravel pathophysiological 
mechanisms in prion diseases, it also supports the notion 
that oligomeric species rather than larger amyloid fibrils 
are the harmful species, a concept that was previously 
suggested for different neurodegenerative diseases (rev. in 
(Caughey and Lansbury, 2003; Haass and Selkoe, 2007). 
It will now be interesting to see how oligomeric PrPSc might 
translocate into the cytosol of scrapie-infected cells and how 
proteasomal impairment contributes to neuronal cell death 
in human prion diseases.
Future directions
To elucidate the mystery of a self-propagating protein 
conformer causing transmissible neurodegenerative 
diseases is a challenging mission, however, research 
on the prion protein has even more to offer. Transgenic 
mouse models paved the way for the intriguing concept 
that the infectious particle and the neurotoxic agent in prion 
diseases might be two distinct species. The existence of 
discrete conformers would also explain the phenomenon of 
sub-clinical prion infection (Hill et al., 2000). The question 
remains whether neurodegenerative diseases induced by 
neurotoxic PrP mutants in the absence of infectious prion 
propagation are genuine models for naturally occurring 
prion diseases. However, the established animal and 
cell culture models are extremely valuable to address an 
essential question in neurodegenerative disease research: 
How do aberrant protein conformers activate toxic signaling 
pathways in neuronal cells?
 In addition to disease-related features, basic research on 
the prion protein provided new insight into cellular pathways 
of general interest. For example, studies employing PrP 
helped to reveal that the ribosome-nascent chain complex 
attached to the translocon complex is more dynamic 
than previously appreciated and that a co-translocational 
regulation of ER import provides an effcient mechanism to 
control loading of the ER with secretory pathway proteins. 
After all, understanding the cellular biology of disease-
associated proteins is the essential prerequisite to exlore 
pathomechanistic events and to develop new therapeutic 
strategies.
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